United States · Industrial & Consumer Products · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for Cidara Therapeutics, Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
| ROE | -218.99% | 0.18% | 0.31% | 0.2% | 0.2% | 0.2% |
|---|---|---|---|---|---|---|
| ROA | -120.52% | 0.14% | 0.23% | 0.15% | 0.15% | 0.15% |
| Gross Margin | 100% | 88.5% | 88.47% | 88.34% | 88.42% | 88.15% |
| Total Assets | $214,796.00K | $216,827.56K | $219,025.03K | $221,034.59K | $221,034.59K | $221,034.59K |
| Net Income | -$169,827.00K | $298.73K | $510.84K | $326.00K | $323.25K | $323.27K |